ANTIBODY-BASED DIAGNOSTIC FOR PERIODONTAL DISEASE

描述：(改编自《调查员摘要》)部分患者 强化后不能控制牙齿附着丧失(牙周炎) 口腔卫生疗法。最近，成功的治疗被发现依赖于 论“益”比“病”的流行程度 牙周沟里的细菌。一个基于这一发现的简单程序 提出了一种酶免疫测定法，用于测定血药浓度。 为放线菌属专属。(a-Ab)，这是 有益的植物群。此阶段1提案的具体目标是 比较难治性或非难治性患者的A-Ab浓度 对治疗有反应。高和低的A-Ab浓度将是 由抗原/抗体沉淀得出的截止值分隔 和酶免疫分析。在该值附近，确定高/低 对不稳定的D-抗体的反应需要测量对照抗体 链球菌脂磷壁酸酯(S-Ab)。这一阶段 2目的是确定：(1)治疗是否改变A-Ab浓度 在纵向研究中；(2)A-Ab浓度是否影响 治疗需要；(3)S抗体含量能否用 稳定的代理抗原。建议的化验应能确定 难治性患者比临床技能更快、更准确，或者 病原菌或宿主产生的破坏性酶的检测 牙龈沟。 建议的商业应用：不可用

DESCRIPTION: (Adapted from investigator's Abstract) Some patients cannot control tooth attachment loss (periodontitis) after intensive oral hygiene therapy. Recently, successful therapy was found to depend on an increased prevalence of "beneficial" relative to "pathogenic" bacteria in gingival sulci. A simple procedure based on this finding is proposed: an enzyme immunoassay to measure the concentration of specific for Actinomyces spp. (A-Ab), a major component of the beneficial flora. The specific aim of this Phase 1 proposal is to compare the A-Ab concentration in patients who are either refractory or responsive to therapy. High and low A-Ab concentrations will be separated by a cutoff value derived from antigen/antibody precipitation and enzyme immunoassay. Near this value, the determination of high/low A-Ab response requires measuring a control antibody, to unstable D- alanyl esters of lipoteichoic acid from streptococci (S-Ab). The Phase 2 aims are to determine: (1) whether therapy alters A-Ab concentration in longitudinal studies; (2) whether A-Ab concentration affects treatment needs; and (3) whether S-Ab content can be measured with stable surrogate antigens. The proposed assay should identify refractory patients faster and more accurately than clinical skills, or assays for pathogenic bacteria or host-produced destructive enzymes at gingival sulci. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE